Our venture capital fund focuses investments on early-stage life sciences companies looking to improve people’s outcomes with cancer.

Recent News

NextRNA-Logo-FullColor-400
09/26/2024

NextRNA Therapeutics Expands Executive Team with Appointment of Jesse Smith, PhD as Chief Scientific Officer

READ MORE
C4-logo-wht
09/13/2024

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

READ MORE
C4-logo-wht
09/10/2024

C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen

READ MORE
NextRNA-Logo-FullColor-400
09/10/2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

READ MORE
C4-logo-wht
09/08/2024

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

READ MORE
C4-logo-wht
09/03/2024

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors

READ MORE
C4-logo-wht
08/29/2024

C4 Therapeutics to Participate in Upcoming September Investor Conferences

READ MORE
NextRNA-Logo-FullColor-400
08/28/2024

Bayer and NextRNA Therapeutics enter strategic collaboration to develop small molecules targeting long non-coding RNAs (lncRNAs) in Oncology

READ MORE
NextRNA-Logo-FullColor-400
08/28/2024

Bayer pens $547M biobucks pact with biotech pushing the boundaries of noncoding RNA

READ MORE

PORTFOLIO HIGHLIGHTS

WUGEN Logo
White C4 Therapeutics logo
Geneoscopy logo
NextRNA Logo
CareVet Logo
microbial-logo-header300